This electronic document is a “live” template. The various components of your paper [title, text, heads, etc.] are already defined on the style sheet, as illustrated by the portions given in this document. Acute transverse myelitis (ATM) is a rare inflammatory disorder characterized by rapidly evolving motor, sensory, and autonomic dysfunction, which can lead to severe outcomes. The main etiologies include demyelinating diseases, infections, and autoimmune conditions such as systemic lupus erythematosus (SLE). The American College of Rheumatology (ACR) recognizes ATM as one of the 19 neuropsychiatric manifestations of SLE, with an estimated incidence of 1% - 2% among SLE patients. Misdiagnosis is frequent and often associated with significant morbidity and mortality. We report the case of a 23-year-old woman presenting with progressive weakness of the lower limbs, dysesthesias extending from the abdomen to the feet, and sphincter dysfunction. Clinical examination revealed severe paraparesis with a sensory level at T8. MRI of the thoracolumbar spine demonstrated extensive T2 and STIR hyperintensity from T7 to L1, consistent with ATM. Due to inadequate response to initial therapy, cyclophosphamide was administered. After one week of hospitalization, the patient showed partial neurological improvement. Early recognition of transverse myelitis in the context of SLE requires a high index of suspicion. Prompt intervention is essential to prevent severe complications and to reduce morbidity and mortality rates.
References
[1]
Zhang, S., Wang, Z., Zhao, J., Wu, D.i., Li, J., Wang, Q., et al. (2020) Clinical Features of Transverse Myelitis Associated with Systemic Lupus Erythematosus. Lupus, 29, 389-397. https://doi.org/10.1177/0961203320905668
[2]
The American College of Rheumatology Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature (1999) The American College of Rheumatology Nomenclature and Case Definitions for Neuropsychiatric Lupus Syndromes. Arthritis&Rheumatism, 42, 599-608. https://doi.org/10.1002/1529-0131(199904)42:4<599::aid-anr2>3.0.co;2-f
[3]
Fernández-Ávila, D.G., Bernal-Macías, S., Rincón-Riaño, D.N., Gutiérrez Dávila, J.M. and Rosselli, D. (2019) Prevalence of Systemic Lupus Erythematosus in Colombia: Data from the National Health Registry 2012-2016. Lupus, 28, 1273-1278. https://doi.org/10.1177/0961203319864168
[4]
Birnbaum, J., Petri, M., Thompson, R., Izbudak, I. and Kerr, D. (2009) Distinct Subtypes of Myelitis in Systemic Lupus Erythematosus. Arthritis & Rheumatism, 60, 3378-3387.
[5]
Fujieda, Y. (2020) Diversity of Neuropsychiatric Manifestations in Systemic Lupus Erythematosus. ImmunologicalMedicine, 43, 135-141. https://doi.org/10.1080/25785826.2020.1770947
[6]
Rivas-Larrauri, F. and Yamazaki-Nakashimada, M.A. (2016) Systemic Lupus Erythematosus: Is It One Disease? Reumatología Clínica, 12, 274-281.
[7]
Beh, S.C., Greenberg, B.M., Frohman, T. and Frohman, E.M. (2013) Transverse Myelitis. NeurologicClinics, 31, 79-138. https://doi.org/10.1016/j.ncl.2012.09.008
[8]
Hryb, J.P., Chiganer, E., Contentti, E.C., Di Pace, J.L., Lessa, C. and Perassolo, M.B. (2016) Myelitis in Systemic Lupus Erythematosus: Clinical Features, Immunological Profile and Magnetic Resonance Imaging of Five Cases. SpinalCordSeriesandCases, 2, Article No. 16005. https://doi.org/10.1038/scsandc.2016.5
[9]
Katsiari, C.G., Giavri, I., Mitsikostas, D.D., Yiannopoulou, K.G. and Sfikakis, P.P. (2011) Acute Transverse Myelitis and Antiphospholipid Antibodies in Lupus: No Evidence for Anticoagulation. European Journal of Neurology, 18, 556-563.
[10]
Mader, S., Jeganathan, V., Arinuma, Y., Sasaki, T., Takahashi, T. and Fujihara, K. (2018) Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets? Arthritis & Rheumatology, 70, 277-286.
[11]
Tan, C.T., Mao, Z., Qiu, W., Hu, X., Wingerchuk, D.M. and Weinshenker, B.G. (2016) International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders. Neurology, 86, 491-492.
[12]
Krett, J.D., Elsbernd, P., Mertz, S., Kumar, R., Alharbi, H. and Pittock, S.J. (2024) “Lupus Myelitis” Revisited. Neurology: Neuroimmunology & Neuroinflammation, 11, e200329.
[13]
Chiganer, E.H., Hryb, J.P. and Carnero Contentti, E. (2017) Myelitis and Lupus: Clinical Manifestations, Diagnosis and Treatment. Reumatología Clínica, 13, 344-348.
[14]
Padmanabhan, A., Connelly-Smith, L., Aqui, N., Balogun, R.A., Klingel, R., Meyer, E., et al. (2019) Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. Journal of Clinical Apheresis, 34, 171-354. https://doi.org/10.1002/jca.21705
[15]
David, T., Hum, R.M., Sutton, E., McCarthy, A., Isenberg, D. and Rahman, A. (2021) Effectiveness of Rituximab in the Treatment of Neuro-Psychiatric SLE: Results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology, 60, 2753-2762.
[16]
Kundnani, N.R., Singh, A., Dixit, R., Sharma, P., Gupta, N. and Mehta, V. (2024) Biologics in Systemic Lupus Erythematosus. Frontiers in Immunology, 15, Article ID: 11434659.